Highlights MediciNova, Inc.

Equities

MNOV

US58468P2065

Delayed Nasdaq Other stock markets 20:57:46 14/05/2024 BST			5-day change	1st Jan Change
1.48 ^USD	-2.63%		+12.03%	-0.67%

05-09	MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166	05-07	CI
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	03-26	CI
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	03-12	CI
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	01-17	CI
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	12-21	CI
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	12-06	CI
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
MediciNova Secures Patent Notice of Allowance in Canada for Amyotrophic Lateral Sclerosis Combination Treatment	11/10/23	MT
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Canada	10/10/23	CI
MediciNova, Inc. Announces Results of Studies Under BARDA Contract to Develop MN 166 as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury	27/09/23	CI
MediciNova Announces Abstract Regarding MN-166 in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology	18/08/23	CI
MediciNova Says European Patent Office Issued Notice of Intention to Grant on Macular Injury Therapy Application	17/08/23	MT
MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 for the Treatment of Macular Injury in Europe	16/08/23	CI
Fed Minutes Anticipation Lifts Exchange-Traded Funds, Equity Futures Slightly Premarket Wednesday	16/08/23	MT
MediciNova Says European Patent Office Granted New Patent Covering Scleroderma, Systemic Sclerosis Treatment	16/08/23	MT
Medicinova Receives New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe	16/08/23	CI
MediciNova, Inc. Receives New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe	15/08/23	CI
MediciNova Says European Patent Office Issued Notice of Intention to Grant on NASH Treatments Application	15/08/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MediciNova, Inc.

Equities

MNOV

US58468P2065

Highlights

Filters